Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular Lymphomas

During treatment with umbralisib, prophylaxis is recommended for Pneumocystis jirovecii pneumonia and to consider prophylactic antivirals to prevent CMV infection, including CMV reactivation
11 Feb 2021
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 5 February 2021, the US Food and Drug Administration (FDA) granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for the following indications:

  • Adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen;
  • Adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. 

Approval was based on two single-arm cohorts of an open-label, multi-centre, multi-cohort study, UTX-TGR-205 (NCT02793583), in 69 patients with MZL who received at least one prior therapy, including an anti-CD20 containing regimen, and in 117 patients with FL after at least 2 prior systemic therapies. Patients received umbralisib 800 mg orally once daily until disease progression or unacceptable toxicity. 

Efficacy was based on overall response rate (ORR) and duration of response (DoR) using modified 2007 International Working Group criteria assessed by an independent review committee.

For patients with MZL, the ORR was 49% (95% confidence interval [CI] 37.0, 61.6) with 16% achieving complete responses. Median DoR was not reached (95% CI 9.3, NE) in these patients.

For patients with FL, the ORR was 43% (95% CI 33.6, 52.2) with 3% achieving complete responses. Median DoR was 11.1 months (8.3, 16.4).

The most common (>15%) adverse reactions, including laboratory abnormalities, were increased creatinine, diarrhoea-colitis, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anaemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash. Serious adverse reactions occurred in 18% of patients, most often from diarrhoea-colitis and infection. Diarrhoea-colitis and transaminase elevation were the most common reasons for dose modifications.

The prescribing information provides warnings and precautions for adverse reactions including infections, neutropenia, diarrhoea and non-infectious colitis, hepatotoxicity, and severe cutaneous reactions.

The recommended umbralisib dose is 800 mg taken orally once daily with food until disease progression or unacceptable toxicity.

Full prescribing information for Ukoniq is available here.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review for the MZL indication and orphan drug designation was granted for the treatment of MZL and FL.

The MZL and FL indications were granted accelerated approval based on ORR. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings